Document is current
Any future updates will be listed below
-
Authors
Casado, Enrique http://orcid.org/0000-0001-8839-6430
Gómez-Alonso, Carlos
Pintos-Morell, Guillem
Bou-Torrent, Rosa
Barreda-Bonis, Ana Coral
Torregrosa, José Vicente
Broseta-Monzó, José Jesús
Arango-Sancho, Pedro
Chocrón-de-Benzaquen, Sara
Olmedilla-Ishishi, Yoko
Soler-López, Begoña http://orcid.org/0000-0001-5853-2307
-
Funding
Funding for this research was provided by:
Kyowa Kirin Farmacéutica
- License Information
-
More Information
Article History
Received: 15 July 2022
Accepted: 20 August 2023
First Online: 29 August 2023
Declarations
:
: The study was approved by the Research Ethics Committee for Medicinal Products of Hospital Universitario Parc Taulí of Sabadell, Spain (28-July-2020; Reference 2020/695). The study was guided by the basic ethical principles contained in the Declaration of Helsinki in its most recent version where it was applicable, and was completed following the international guidelines of the International Society for Pharmacoepidemiology (ISPE) Good Epidemiology Practices and applicable national and European standards.
: Not applicable to this study.
: Yoko Olmedilla is an employee of Kyowa Kirin Farmaceutica, S.L. Begoña Soler was engaged to carry out the design, monitoring, statistical analysis and management of any publications derived from the study. Guillem Pintos received fees from Kyowa Kirin Farmacéutica, S.L. for coordination of the study, for consulting and as a speaker. José Jesús Broseta received fees for presentations and consulting from Kyowa Kirin. The other authors received fees from Kyowa Kirin Farmaceutica, S.L. for coordination of the study.
